| Name | Title | Contact Details |
|---|
Expansion Therapeutics is a drug discovery and development company pursuing the vast potential of small molecule medicines for RNA-mediated diseases.
InterVenn Biosciences utilizes a proprietary high-throughput glycoproteomic interrogation platform using artificial intelligence and mass spectrometry for next-gen precision medicine. The company is working to find new solutions in ovarian, pancreatic, liver, prostate, and kidney cancer, together with applications from the Vista suite of solutions for treatment and monitoring, immune profiling, patient stratification, and disease progression.
Applied Proteomics Inc. is advancing the application of proteomics to the development of diagnostics, companion diagnostics, and personalized medicine applications to power better medical decisions and care. API has developed a proteomics platform solution to make protein-based biomarker discovery possible as a replicable, industrial application ready to be applied to health diagnostic problems.
Viela Bio is a clinical-stage biotechnology company pioneering and advancing treatments for severe inflammation and autoimmune diseases.
Palvella Therapeutics was founded with the single-minded goal of serving individuals suffering from serious rare genetic diseases with no approved treatments.